T Cell Specific Surface Glycoprotein CD28 Market Size Projected To Increase From $1.78 Billion To $2.57 Billion During The Forecast Period
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
T Cell Specific Surface Glycoprotein CD28 Market Forecast Highlighting Growth From $1.78 Billion To $2.57 Billion
The market size for T cell-specific surface glycoprotein CD28 has experienced notable expansion in recent years. From $1.62 billion in 2025, it is forecasted to reach $1.78 billion by 2026, achieving a compound annual growth rate (CAGR) of 10.0%. This historic growth has been driven by several factors, including the early recognition of CD28 as a co-stimulatory receptor on T cells, heightened focus on immunology research, a growing incidence of autoimmune diseases, increased investment in cancer research efforts, and constraints in the supply of monoclonal antibody therapies.
The market for the T cell-specific surface glycoprotein CD28 is projected to experience robust expansion over the coming years. By 2030, its value is anticipated to reach $2.58 billion, reflecting a compound annual growth rate (CAGR) of 9.7%. This forecasted growth is driven by factors such as the development of lulizumab pegol and novel CD28 inhibitors, the broadening of preclinical and clinical trial activities, the incorporation of CD28-targeted therapies into treatments for autoimmune diseases and cancer, heightened investment in biopharmaceutical research, and progress in immunomodulation and monoclonal antibody engineering. Key trends shaping the forecast period include the growing use of flow cytometry and ELISA technologies, an uptick in immunology and cancer research applications, the emergence of new CD28 inhibitors and biobetters, the expansion of research into stem cells and autoimmune disorders, and the inclusion of lulizumab pegol in preclinical and clinical investigations.
Download A Free Sample Report For Comprehensive Market Insights:
T Cell Specific Surface Glycoprotein CD28 Market Opportunity Drivers: What Is Creating New Revenue Potential?
The rising focus on personalized medicine is anticipated to fuel the expansion of the T cell-specific surface glycoprotein CD28 market in the coming period. Defined as a healthcare strategy that customizes treatments for individuals by taking into account their genetic makeup, environmental exposures, and lifestyle habits, personalized medicine aims to enhance outcomes and improve the quality of care. Its adoption is accelerating, driven by progress in genomic technologies that allow for accurate detection of genetic differences and the development of customized therapies. By facilitating targeted immune modulation, the T cell-specific surface glycoprotein CD28 contributes to personalized medicine, increasing the precision and effectiveness of treatments. This approach improves therapeutic results through the promotion of optimal T cell activation, thereby boosting immune responses specific to each patient. As an example, the Personalized Medicine Coalition (PMC), a nonprofit organization based in the United States, reported in February 2024 that the U.S. Food and Drug Administration (FDA) gave approval to 26 new personalized medicines during 2023, a notable rise from the 12 approvals recorded in 2022. Consequently, the growing emphasis on personalized medicine is driving the growth of the T cell-specific surface glycoprotein CD28 market.
T Cell Specific Surface Glycoprotein CD28 Market Segment Landscape: Which Areas Lead Market Development?
The t cell specific surface glycoprotein cd28 market covered in this report is segmented –
1) By Type: FPT 155, FR 104, Lulizumab Pegol, Other Types
2) By Technology: Flow Cytometry, EnzymeLinked Immunosorbent Assay (ELISA), Polymerase Chain Reaction (PCR), Weste Blotting, Immunohistochemistry
3) By Distribution Channel: Direct Sales, Distributors, Ecommerce, Retail Pharmacies, Wholesalers
4) By Application: Immunology Research, Cancer Research, Autoimmune Diseases, Infectious Diseases, Stem Cell Research
5) By End-User: Hospitals, Research Laboratories, Academic Institutions, Pharmaceutical Companies, Diagnostic Laboratories
Subsegments:
1) By FPT 155: Preclinical Studies, Clinical Trials, Oncology Applications, Licensing And Partnerships
2) By FR 104: Autoimmune Disease Applications, Rheumatoid Arthritis Trials, Transplant Rejection Studies, Research Collaborations
3) By Lulizumab Pegol: Systemic Lupus Erythematosus (SLE) Studies, Immunomodulation Research, Biopharmaceutical Development, Monoclonal Antibody Engineering
4) By Other Types: Novel CD28 Inhibitors, Combination Therapies, Biosimilars And Biobetters, Emerging Research Compounds
T Cell Specific Surface Glycoprotein CD28 Market Innovation Trends Driving Future Development
Key players in the T cell-specific surface glycoprotein CD28 market are prioritizing the creation of advanced solutions, particularly combination immunotherapies, with the goal of improving T cell activation, anticancer effectiveness, and overall patient outcomes. These combination immunotherapies employ several immune-focused strategies together to strengthen the body’s ability to combat diseases. A notable example occurred in February 2025, when Rondo Therapeutics Inc., a biopharmaceutical firm based in the US, shared preclinical findings for RNDO 564, a pioneering CD28 Nectin-4 costimulatory bispecific antibody designed for advanced bladder cancer. This agent is specifically formulated to trigger CD28 on T cells once it attaches to Nectin-4 on tumor cells, thereby boosting T-cell-mediated destruction of cancer cells and reducing unintended toxic effects. The results showed strong antitumor activity in preclinical models, paving the way for its continued development as a possible treatment for individuals with metastatic urothelial carcinoma.
T Cell Specific Surface Glycoprotein CD28 Market Industry Leaders And Market Competition
Major companies operating in the t cell specific surface glycoprotein cd28 market are Gilead Sciences Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, Sino Biological Inc., Xencor Inc., ACROBiosystems Co. Ltd., Fate Therapeutics Inc., Medigene AG, Alpine Immune Sciences Inc., Adaptimmune Therapeutics plc, OSE Immunotherapeutics SA, Creative Biolabs Inc., Rondo Therapeutics Inc.
Access The Complete T Cell Specific Surface Glycoprotein CD28 Market Report:
T Cell Specific Surface Glycoprotein CD28 Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the T cell-specific surface glycoprotein CD28 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the t cell specific surface glycoprotein cd28 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
